10 studies found for:    "Acquired hemophilia"
Show Display Options
Download search resultsDownload the search results for:
"Acquired hemophilia" (10 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown  Turkish Acquired Haemophilia Registry
Condition: Acquired Haemophilia
Intervention: Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin
2 Recruiting Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Condition: Acquired Haemophilia
Interventions: Drug: Steroid + cyclophosphamide;   Drug: Steroid + rituximab
3 Completed Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study
Conditions: Acquired Haemophilia;   Register
Intervention:
4 No longer available Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Condition: Acquired Hemophilia A
Intervention: Biological: OBI-1
5 Completed Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia
Conditions: Acquired Bleeding Disorder;   Acquired Haemophilia
Intervention: Drug: activated recombinant human factor VII
6 Completed Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
Conditions: Congenital Bleeding Disorder;   Congenital FVII Deficiency;   Glanzmann's Disease;   Acquired Bleeding Disorder;   Acquired Haemophilia
Intervention: Drug: activated recombinant human factor VII
7 Completed Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Condition: Hemophilia A
Intervention: Biological: OBI-1
8 Terminated Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
Condition: Hemophilia A
Interventions: Drug: Rituxan;   Drug: prednisone
9 Completed Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
Conditions: Acquired Bleeding Disorder;   Acquired Haemophilia;   Congenital Bleeding Disorder;   Congenital FVII Deficiency;   Glanzmann's Disease;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors;   Healthy
Intervention: Drug: activated recombinant human factor VII
10 Recruiting Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
Condition: Haemophilia
Intervention:

Indicates status has not been verified in more than two years